Search results
Showing 201 to 250 of 298 results for breast cancer
guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101 Date issued
combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued
increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and...
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
Biographies and registered interests for members of the Technology Appraisal Committee A
In development [GID-TA11318] Expected publication date: TBC
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
years whose record shows a breast screening test has been performed within the last 3 years Subject(s): Cancer Date of
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
by day. Having an abortion does not increase the risk of infertility, breast cancer or mental health issues. You can usually choose...
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks
by day. Having an abortion does not increase the risk of infertility, breast cancer or mental health issues. You can usually choose...
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)
NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
This guidance has been updated and replaced by NICE guideline CG164.
This guidance has been updated and replaced by NICE guideline CG41.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].
This guidance has been replaced by NICE guideline CG81.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Early and locally advanced breast cancer: diagnosis and treatment (CG80)
This guideline has been updated and replaced by NICE guideline NG101.
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101. This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
Interim methods guide for developing service guidance 2014 (PMG8)
Interim methods guide for developing service guidance 2014
This guideline has been updated and replaced by NICE guideline NG101. This guidance has been updated and replaced by NICE technology appraisal guidance 687.
This guidance has been updated and replaced by NICE technology appraisal guidance 836.